ArticleCell biochemistry and function2026
HBQ1 Acts as a Prognostic Biomarker and Tumor Suppressor Linked to Antigen Presentation in Glioma.
Article in Cell biochemistry and function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioma is a highly aggressive brain tumor associated with substantial morbidity and mortality and with limited treatment options. This study investigates the functional role of Hemoglobin Subunit Theta 1 (HBQ1) in glioma and evaluates its potential as a prognostic biomarker. Using integrated bioinformatics approaches, we demonstrated that HBQ1 expression was significantly downregulated in glioma tissues compared to normal brain tissues and was inversely correlated with tumor grade. Survival analysis indicated that lower HBQ1 expression is associated with poorer overall survival and disease-free survival. Functional enrichment analyses connected HBQ1 to key pathways including antigen presentation (MHC II), calcium signaling, mitogen‑activated protein kinase (MAPK) signaling, and γ‑aminobutyric acid (GABA)‑ergic synapse. In vitro, overexpression of HBQ1 in U87 cells markedly suppressed proliferation, migration, and invasion, while enhancing antigen presentation. Moreover, HBQ1 expression was significantly correlated with important molecular markers such as isocitrate dehydrogenase (IDH) mutation, 1p/19q co-deletion, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, as well as with genes involved in glutamate-GABA metabolism. Collectively, our findings identify HBQ1 as a novel prognostic biomarker and a potential tumor suppressor in glioma, possibly through modulating the immune microenvironment and neuron-glioma crosstalk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.